Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines

International Journal of Cancer

Volumn 97, Issue 4, 2002, Pages 481-488

  Caca, Karel ^a   Feisthammel, Jürgen ^a   Klee, Karen ^a   Tannapfel, Andrea ^a   Witzigmann, Helmut ^a   Wittekind, Christian ^a   Mössner, Joachim ^a   Berr, Frieder ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Bile tract cancer; Histopathology; INK4a ARF; P53; Promoter hypermethylation

Indexed keywords

PROTEIN P53;

ARTICLE; BILIARY TRACT CANCER; CANCER CELL CULTURE; CHROMOSOME 9P; DNA METHYLATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILIARY TRACT NEOPLASMS; BLOTTING, WESTERN; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GALLBLADDER NEOPLASMS; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036466856     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1639     Document Type: Article

References (61)

1. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates
2. Biliary tract cancers
3. Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded)
4. What constitutes long term survival after surgery for hilar cholangiocarcinoma?
5. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma
6. Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival
7. Photodynamic therapy of nonresectable cholangiocarcinoma
8. A genetic model for colorectal tumorigenesis
9. Cancer progression
10. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas
11. p53 mutagenesis in Klatskin tumors
12. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma
13. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand
14. Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area
15. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas
16. Role of the p16 tumor suppressor gene in cancer
17. The p16INK4a/CDKN2A tumor suppressor and its relatives
18. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status
19. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia
20. Somatic INK4a-ARF locus mutations: A significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck
21. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers
22. Frequency of p16(INK4A) alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver
23. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma
24. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
25. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
26. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
27. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
28. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53
29. In vitro interaction of α-difluoromethyl-ornithine (DFMO) and human recombinant interferon-γ (rIFN-γ) on human cancer cell lines
30. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1
31. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells
32. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines
33. Cultured human gallbladder epithelia. Methods and partial characterization of a carcinomaderived model
34. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas
35. Germ-line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma
36. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas
37. Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors
38. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia
39. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence
40. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia
41. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer
42. "Natural history" of unresected cholangiocarcinoma: Patient outcome after noncurative intervention
43. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
44. Germline p16 mutations in familial melanoma
45. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas
46. A cell cycle regulator potentially involved in genesis of many tumor types
47. p16INK4a: A gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression
48. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma
49. Multiple, unique, and common p53 mutations in a thorotrast recipient with four primary cancers
50. K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients
51. New p53 mutations in hilar cholangiocarcinoma
52. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas
53. Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer
54. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct
55. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival
56. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts
57. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas
58. p53: A cell cycle regulator activated by DNA damage
59. p53 gene mutations inside and outside of exons 5-8: The patterns differ in breast and other cancers
60. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions
61. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression